13
views
0
recommends
+1 Recommend
2 collections
    0
    shares

      To submit to this journal, click here

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Impact of COVID-19 pandemic on bone marrow transplantation in Morocco

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To the editors of Pan African Medical Journal The novel coronavirus (COVID-19) pandemic is the defining global health crisis of our time and the greatest threat we have faced during this century. As a highly contagious virus, the infection emerged in China in January 2020 [1] and rapidly spread globally; with the most affected regions being the USA, Europe, Republic of Korea and Iran. According to the World Health Organizations´ (WHO) data, in April 2020, one million of the population has been infected with more than 50 000 deaths [2]. To date, in the absence of any specific treatment, our knowledge about this disease remains very limited and is subject to rapid change. Cancer is considered a risk factor for COVID-19 infection (1%) [3], with very few cases reported in hematology-Oncology, but with no data related to bone marrow transplant. This virus represents a serious danger for patients with hematologic malignancies scheduled for bone marrow transplant due to myeloablative conditioning and immunosuppressive treatments. People receiving chemotherapy with compromised immune systems and complications after stem cell transplant have an increased risk for infection [4]. During a bone marrow transplant, pulmonary complications are frequent and associated to death [5]. COVID-19 infection may complicate clinical symptoms with higher risk of respiratory distress [6], and this situation could be even more critical depending on factors of co-morbidity such as age, cardiovascular, liver and kidney diseases [7]. In addition to the virulence of the infection, restrictive government measures cause many obstacles and difficulties for the transplant course: 1) blood transfusion is vital for transplant patients; the number of blood donors decreases drastically with population confinement, 2) drug manufacturing and available medicines are compromised, 3) the allogenic stem cell transplant with donors on international files becomes very difficult to access because of the international borders shut down, 4) Management of unstable patients requires an intensive care unit with mechanical ventilation, however, depending on the pandemic level and the healthcare system in each country, hospital beds might be lacking. Therefore, the management of patients transplanted during a pandemic is very complex. To overcome this crisis, some recommendations and emergency measures have been developed by scientific societies like the European Society for Blood and Bone Marrow Transplantation [8,9]. Their guidelines are established according to the coronavirus high contagion rate in Europe. The most important messages are the postponement of any low-risk non-urgent transplant, and freezing rich grafts if mobilization is already scheduled. Currently, virus detection has become mandatory before any transplant process, among donors as well as recipients for allogenic stem cell transplant using throat-swab specimens for PCR test. During the transplant period, detection must be carried out before any symptom like fever, cough or chest imaging abnormalities. Prevention procedures remain a very useful mean to avoid infection, and the WHO recommendations must be diligently followed by healthcare staff, patients and donors. It is vital to be very careful with hygiene routines, including hand washing, use of protective mask, alcohol-containing hand sanitizers, and limited visits. In post-transplant follow-up period, it is recommended to prioritize telemedicine consultations if possible. In Morocco, the situation is less critical than in Europe, with a record of 1184 confirmed cases with 90 deaths [10]. The government has adopted containment measures very early but the contagion is still gaining ground, and to ensure the safety of our transplanted patients, our hematology centers have adopted actions based on the European recommendations. In the Table 1, we summarize the main practical steps that can be taken to reduce the risk to our vulnerable patients during bone marrow transplant [8]. Table 1 practical recommendations for bone marrow transplant during COVID-19 pandemic Prioritizing stem cell transplant - Prioritize urgent patients with high risk of disease progression and high grade malignancy. - Defer transplant if possible, for patients with low risk progression, poor outcome or high risk of immunosuppression. - Make decisions and discuss the risks and benefits as part of a multidisciplinary team. Hygiene Procedures - Follow strict hygiene procedures for patients, donors, medical staff and visitors. - Isolate suspected patients and infected persons. - Limit access to unit transplants. Recommendations for recipients - COVID-19 testing in all candidates before any steps of transplantation. - Defer transplant in positive patients, and in any suspect contact or contagion of COVID-19. - Test and explore any patients with symptoms of COVID-19. Recommendations for donors - Exclude positive person and suspected contagion. - Test all donors before harvesting stem cell. - Mobilization of stem cell with growth factors without chemotherapy. - Collect a rich graft and cryopreservation if possible. Treatment of COVID-19 Infection - No guidelines for treatment. - Potential treatment with hydroxychloroquine with azithromycin, lopinavir/ritonavir, tocilizumab. Conclusion The situation is critical all over the world and restrictive measures will affect bone marrow transplantation as the COVID-19 is spreading. It is necessary to carefully follow all international recommendations; Morocco has therefore taken emergency measures to minimize the impact of COVID-19 on transplant activity. Competing interests All authors declare no competing interests.

          Related collections

          Most cited references6

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

          Summary Background Since December, 2019, Wuhan, China, has experienced an outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Epidemiological and clinical characteristics of patients with COVID-19 have been reported but risk factors for mortality and a detailed clinical course of illness, including viral shedding, have not been well described. Methods In this retrospective, multicentre cohort study, we included all adult inpatients (≥18 years old) with laboratory-confirmed COVID-19 from Jinyintan Hospital and Wuhan Pulmonary Hospital (Wuhan, China) who had been discharged or had died by Jan 31, 2020. Demographic, clinical, treatment, and laboratory data, including serial samples for viral RNA detection, were extracted from electronic medical records and compared between survivors and non-survivors. We used univariable and multivariable logistic regression methods to explore the risk factors associated with in-hospital death. Findings 191 patients (135 from Jinyintan Hospital and 56 from Wuhan Pulmonary Hospital) were included in this study, of whom 137 were discharged and 54 died in hospital. 91 (48%) patients had a comorbidity, with hypertension being the most common (58 [30%] patients), followed by diabetes (36 [19%] patients) and coronary heart disease (15 [8%] patients). Multivariable regression showed increasing odds of in-hospital death associated with older age (odds ratio 1·10, 95% CI 1·03–1·17, per year increase; p=0·0043), higher Sequential Organ Failure Assessment (SOFA) score (5·65, 2·61–12·23; p<0·0001), and d-dimer greater than 1 μg/mL (18·42, 2·64–128·55; p=0·0033) on admission. Median duration of viral shedding was 20·0 days (IQR 17·0–24·0) in survivors, but SARS-CoV-2 was detectable until death in non-survivors. The longest observed duration of viral shedding in survivors was 37 days. Interpretation The potential risk factors of older age, high SOFA score, and d-dimer greater than 1 μg/mL could help clinicians to identify patients with poor prognosis at an early stage. Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future. Funding Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences; National Science Grant for Distinguished Young Scholars; National Key Research and Development Program of China; The Beijing Science and Technology Project; and Major Projects of National Science and Technology on New Drug Creation and Development.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

            China and the rest of the world are experiencing an outbreak of a novel betacoronavirus known as severe acute respiratory syndrome corona virus 2 (SARS-CoV-2). 1 By Feb 12, 2020, the rapid spread of the virus had caused 42 747 cases and 1017 deaths in China and cases have been reported in 25 countries, including the USA, Japan, and Spain. WHO has declared 2019 novel coronavirus disease (COVID-19), caused by SARS-CoV-2, a public health emergency of international concern. In contrast to severe acute respiratory system coronavirus and Middle East respiratory syndrome coronavirus, more deaths from COVID-19 have been caused by multiple organ dysfunction syndrome rather than respiratory failure, 2 which might be attributable to the widespread distribution of angiotensin converting enzyme 2—the functional receptor for SARS-CoV-2—in multiple organs.3, 4 Patients with cancer are more susceptible to infection than individuals without cancer because of their systemic immunosuppressive state caused by the malignancy and anticancer treatments, such as chemotherapy or surgery.5, 6, 7, 8 Therefore, these patients might be at increased risk of COVID-19 and have a poorer prognosis. On behalf of the National Clinical Research Center for Respiratory Disease, we worked together with the National Health Commission of the People's Republic of China to establish a prospective cohort to monitor COVID-19 cases throughout China. As of the data cutoff on Jan 31, 2020, we have collected and analysed 2007 cases from 575 hospitals (appendix pp 4–9 for a full list) in 31 provincial administrative regions. All cases were diagnosed with laboratory-confirmed COVID-19 acute respiratory disease and were admitted to hospital. We excluded 417 cases because of insufficient records of previous disease history. 18 (1%; 95% CI 0·61–1·65) of 1590 COVID-19 cases had a history of cancer, which seems to be higher than the incidence of cancer in the overall Chinese population (285·83 [0·29%] per 100 000 people, according to 2015 cancer epidemiology statistics 9 ). Detailed information about the 18 patients with cancer with COVID-19 is summarised in the appendix (p 1). Lung cancer was the most frequent type (five [28%] of 18 patients). Four (25%) of 16 patients (two of the 18 patients had unknown treatment status) with cancer with COVID-19 had received chemotherapy or surgery within the past month, and the other 12 (25%) patients were cancer survivors in routine follow-up after primary resection. Compared with patients without cancer, patients with cancer were older (mean age 63·1 years [SD 12·1] vs 48·7 years [16·2]), more likely to have a history of smoking (four [22%] of 18 patients vs 107 [7%] of 1572 patients), had more polypnea (eight [47%] of 17 patients vs 323 [23%] of 1377 patients; some data were missing on polypnea), and more severe baseline CT manifestation (17 [94%] of 18 patients vs 1113 [71%] of 1572 patients), but had no significant differences in sex, other baseline symptoms, other comorbidities, or baseline severity of x-ray (appendix p 2). Most importantly, patients with cancer were observed to have a higher risk of severe events (a composite endpoint defined as the percentage of patients being admitted to the intensive care unit requiring invasive ventilation, or death) compared with patients without cancer (seven [39%] of 18 patients vs 124 [8%] of 1572 patients; Fisher's exact p=0·0003). We observed similar results when the severe events were defined both by the above objective events and physician evaluation (nine [50%] of 18 patients vs 245 [16%] of 1572 patients; Fisher's exact p=0·0008). Moreover, patients who underwent chemotherapy or surgery in the past month had a numerically higher risk (three [75%] of four patients) of clinically severe events than did those not receiving chemotherapy or surgery (six [43%] of 14 patients; figure ). These odds were further confirmed by logistic regression (odds ratio [OR] 5·34, 95% CI 1·80–16·18; p=0·0026) after adjusting for other risk factors, including age, smoking history, and other comorbidities. Cancer history represented the highest risk for severe events (appendix p 3). Among patients with cancer, older age was the only risk factor for severe events (OR 1·43, 95% CI 0·97–2·12; p=0·072). Patients with lung cancer did not have a higher probability of severe events compared with patients with other cancer types (one [20%] of five patients with lung cancer vs eight [62%] of 13 patients with other types of cancer; p=0·294). Additionally, we used a Cox regression model to evaluate the time-dependent hazards of developing severe events, and found that patients with cancer deteriorated more rapidly than those without cancer (median time to severe events 13 days [IQR 6–15] vs 43 days [20–not reached]; p<0·0001; hazard ratio 3·56, 95% CI 1·65–7·69, after adjusting for age; figure). Figure Severe events in patients without cancer, cancer survivors, and patients with cancer (A) and risks of developing severe events for patients with cancer and patients without cancer (B) ICU=intensive care unit. In this study, we analysed the risk for severe COVID-19 in patients with cancer for the first time, to our knowledge; only by nationwide analysis can we follow up patients with rare but important comorbidities, such as cancer. We found that patients with cancer might have a higher risk of COVID-19 than individuals without cancer. Additionally, we showed that patients with cancer had poorer outcomes from COVID-19, providing a timely reminder to physicians that more intensive attention should be paid to patients with cancer, in case of rapid deterioration. Therefore, we propose three major strategies for patients with cancer in this COVID-19 crisis, and in future attacks of severe infectious diseases. First, an intentional postponing of adjuvant chemotherapy or elective surgery for stable cancer should be considered in endemic areas. Second, stronger personal protection provisions should be made for patients with cancer or cancer survivors. Third, more intensive surveillance or treatment should be considered when patients with cancer are infected with SARS-CoV-2, especially in older patients or those with other comorbidities.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found

              The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance

                Bookmark

                Author and article information

                Journal
                Pan Afr Med J
                Pan Afr Med J
                PAMJ
                The Pan African Medical Journal
                The African Field Epidemiology Network
                1937-8688
                16 April 2020
                2020
                : 35
                : Suppl 2
                : 5
                Affiliations
                [1 ]Department of Hematology, International University Hospital Cheikh Khalifa Ibn Zayd, Casablanca, Morocco
                [2 ]Mohammed VI University of Health Sciences, Casablanca, Morocco
                Author notes
                [& ] Corresponding author: Maryame Ahnach, Department of Hematology, International University Hospital Cheikh Khalifa Ibn Zayd, Casablanca, Morocco
                Article
                PAMJ-SUPP-35-2-05
                10.11604/pamj.2020.35.5.22619
                7266477
                6827918a-85fb-401c-b571-2e9153aaa5dd
                © Maryame Ahnach et al.

                The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 02 April 2020
                : 10 April 2020
                Categories
                Letter to the Editors

                Medicine
                covid 19,allogenic,autologous,stem cell transplantation
                Medicine
                covid 19, allogenic, autologous, stem cell transplantation

                Comments

                Comment on this article